Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial

The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25 mg with telmisartan 80 mg plus amlodipine 5 mg in hypertensive patients. This is a multicenter, double‐blind, active‐controlled, phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Eun Joo, Kim, Moo Hyun, Kim, Young‐Hak, Chang, Kiyuk, Choi, Dong‐Ju, Kang, Woong Chol, Shin, Jinho, Kim, Seong Hwan, Lee, Namho, Son, Jang Won, Doh, Joon‐Hyung, Kim, Woo‐Shik, Hong, Soon Jun, Rhee, Moo‐Yong, Ahn, Youngkeun, Lim, Sang‐Wook, Hong, Seung Pyo, Choi, So‐Yeon, Hyon, Min Su, Hwang, Jin‐Yong, Kwon, Kihwan, Cha, Kwang Soo, Ihm, Sang‐Hyun, Lee, Jae‐Hwan, Yoo, Byung‐Su, Kim, Hyo‐Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497032/
https://www.ncbi.nlm.nih.gov/pubmed/37614053
http://dx.doi.org/10.1111/jch.14707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497032/
https://www.ncbi.nlm.nih.gov/pubmed/37614053
http://dx.doi.org/10.1111/jch.14707

Ejemplares similares